Sculpting humoral immunity through dengue vaccination to enhance protective immunity

Sculpting humoral immunity through dengue vaccination to enhance protective immunity

Dengue viruses (DENV) are the most important mosquito transmitted viral pathogens infecting humans. DENV infection produces a spectrum of disease, most commonly causing a self-limiting flu-like illness known as dengue fever; yet with increased frequency, manifesting as life-threatening dengue hemorr...

Full description

Bibliographic Details
Main Authors:	Wayne eCrill, Holly R Hughes, Nicole B Trainor, Brent S Davis, Matt T Whitney, Gwong-Jen J Chang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2012-11-01
Series:	Frontiers in Immunology
Subjects:	Antibody-Dependent Enhancement Dengue Dengue Vaccines vaccine safety DNA Vaccines Immune Refocusing
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fimmu.2012.00334/full

Similar Items

Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement
by: Hughes Holly R, et al.
Published: (2012-06-01)

Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice
by: Zhang Quanfu, et al.
Published: (2011-06-01)

Implications of Dengue Virus Maturation on Vaccine Induced Humoral Immunity in Mice
by: Connor A. P. Scott, et al.
Published: (2021-09-01)

Call to Action for Dengue Vaccine Failure
by: Suresh Mahalingam, et al.
Published: (2013-08-01)

Clinical development update: 1st dengue vaccine candidate
by: Alain Bouckenooghe
Published: (2016-02-01)

Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine
by: Rahul Shukla, et al.
Published: (2020-10-01)

Utility, limitations and future of non-human primates for dengue research and vaccine development
by: Laura eWhite, et al.
Published: (2014-09-01)

A Model of Vaccination for Dengue in the Philippines 2016–2018
by: Pierre Magal, et al.
Published: (2021-10-01)

Multi-walled carbon nanotubes functionalized with recombinant Dengue virus 3 envelope proteins induce significant and specific immune responses in mice
by: Alice F. Versiani, et al.
Published: (2017-04-01)

Expression of Dengue virus envelope glycoproteins using a Measles vaccine vector
Published: (2013)

Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice
by: Xiaoyan Zheng, et al.
Published: (2017-05-01)

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy
by: Maia A Rabaa, et al.
Published: (2017-09-01)

Addition of Partial Envelope Domain II into Envelope Domain III of Dengue Virus Antigen Potentiates the Induction of Virus-Neutralizing Antibodies and Induces Protective Immunity
by: Jisang Park, et al.
Published: (2020-02-01)

Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1
by: Heather Friberg, et al.
Published: (2020-01-01)

Targets and strategies for vaccine development against dengue viruses
by: Wen-Hung Wang, et al.
Published: (2021-12-01)

Adapting Rapid Diagnostic Tests to Detect Historical Dengue Virus Infections
by: Fernando Echegaray, et al.
Published: (2021-07-01)

When Can One Vaccinate with a Live Vaccine after Wild-Type Dengue Infection?
by: Bruno Guy, et al.
Published: (2020-04-01)

Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults
by: Judith Kirstein, et al.
Published: (2018-09-01)

Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development
by: Anna P. Durbin, et al.
Published: (2011-09-01)

Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?
by: Ada Maria Barcelos Alves, et al.
Published: (2021-04-01)

Acceptability of the dengue vaccination among parents in urban poor communities of Quezon City, Philippines before and after vaccine suspension
by: Ezra M. Valido, et al.
Published: (2018-09-01)

Recent Developments in Recombinant Protein–Based Dengue Vaccines
by: Nagesh K. Tripathi, et al.
Published: (2018-08-01)

Seroepidemiology of dengue virus infection among adults during the ending phase of a severe dengue epidemic in southern Taiwan, 2015
by: Yu-Wen Chien, et al.
Published: (2019-04-01)

Immune Responses to Dengue and Zika Viruses—Guidance for T Cell Vaccine Development
by: Claude Roth, et al.
Published: (2018-02-01)

Enhancement of Tetravalent Immune Responses to Highly Conserved Epitopes of a Dengue Peptide Vaccine Conjugated to Polystyrene Nanoparticles
by: Yanqi Chan, et al.
Published: (2020-07-01)

Maternal Immunity and Vaccination Influence Disease Severity in Progeny in a Novel Mast Cell-Deficient Mouse Model of Severe Dengue
by: Chinmay Kumar Mantri, et al.
Published: (2021-05-01)

Systematic review of dengue vaccine efficacy
by: Lucia Teresa Côrtes da Silveira, et al.
Published: (2019-08-01)

A Review on Dengue Vaccine Development
by: Sheng-Qun Deng, et al.
Published: (2020-02-01)

Optimal Control of Dengue Transmission with Vaccination
by: Anusit Chamnan, et al.
Published: (2021-08-01)

Successive Immunization With Epitope-Decreasing Dengue Antigens Induced Conservative Anti-Dengue Immune Responses
by: Jue Hou, et al.
Published: (2020-09-01)

Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
by: Adam T. Waickman, et al.
Published: (2019-07-01)

Mouse models to study dengue virus immunology and pathogenesis
by: Raphaël M. Zellweger, et al.
Published: (2014-04-01)

Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?
by: Lucas Wilken, et al.
Published: (2020-06-01)

Advances in prevention and control for dengue fever
by: LI Jintao
Published: (2019-10-01)

A Comparison between the Predictors of Vaccine Uptake Intentions for Influenza and Dengue
by: Chitra Panchapakesan, et al.
Published: (2018-11-01)

Human Immune Responses to Dengue Virus Infection: lessons learned from prospective cohort studies
by: Timothy P Endy
Published: (2014-04-01)

Seguridad e inmunogenicidad en ensayos clínicos de vacunas para Dengue
by: Janeth Catalina Reyes Castaño, et al.

Long-term safety follow-up of children from a randomized—controlled phase II b proof—of—concept efficacy study of the live, attenuated, tetravalent dengue vaccine (CYD—TDV) in Thailand
by: Kriengsak Limkittikul, et al.
Published: (2019-01-01)

Protective Role of Cross-Reactive CD8 T Cells Against Dengue Virus Infection
by: Annie Elong Ngono, et al.
Published: (2016-11-01)

Persistent Emergence of Dengue
by: Charles H. Calisher
Published: (2005-05-01)